evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

OUTBACK re‐entry catheter vs manual re‐entry

months' patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions

OUTBACK re‐entry catheter showed no clear difference in months' patency rate compared with manual re‐entry (low certainty).

2 findings from 1 review

OUTBACK re‐entry catheter vs manual re‐entry

Primary patency ( · 52 people with TASC‐II D superficial femoral artery chronic total occlusions
2 findings from 1 review